Full TitleA Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion
The purpose of this study is to find the highest dose of the investigational drug MRTX1719 that can be given safely to people with solid tumors that have continued to grow despite prior treatment and contain a specific change in a gene called MTAP.
MRTX1719 works against cancer by blocking a protein called PRMT5, which is increased in tumors with MTAP deletions. PRMT5 contributes to tumor growth, so inhibiting it may slow or stop the growth of a tumor. MRTX1719 is taken orally (by mouth).
To be eligible for this study, patients must meet several requirements, including:
- Participants must have inoperable or metastatic solid tumors that contain a mutation called the “homozygous MTAP deletion.”
- At least 2 weeks must pass between the completion of previous therapies and receipt of MRTX1719.
- Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
- This study is for people age 18 and older.
For more information and to ask about eligibility for this study, please contact the office of Dr. Kathryn Arbour at 646-608-3792.